KR20170017915A - 멜록시캄의 신규 제형 - Google Patents

멜록시캄의 신규 제형 Download PDF

Info

Publication number
KR20170017915A
KR20170017915A KR1020167034671A KR20167034671A KR20170017915A KR 20170017915 A KR20170017915 A KR 20170017915A KR 1020167034671 A KR1020167034671 A KR 1020167034671A KR 20167034671 A KR20167034671 A KR 20167034671A KR 20170017915 A KR20170017915 A KR 20170017915A
Authority
KR
South Korea
Prior art keywords
meloxicam
minutes
less
single dose
healthy adult
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167034671A
Other languages
English (en)
Korean (ko)
Inventor
에이치. 윌리엄 보쉬
Original Assignee
아이슈티카 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54768708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170017915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아이슈티카 피티와이 리미티드 filed Critical 아이슈티카 피티와이 리미티드
Publication of KR20170017915A publication Critical patent/KR20170017915A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020167034671A 2014-06-09 2015-06-09 멜록시캄의 신규 제형 Ceased KR20170017915A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009860P 2014-06-09 2014-06-09
US62/009,860 2014-06-09
US14/675,410 US9526734B2 (en) 2014-06-09 2015-03-31 Formulation of meloxicam
US14/675,410 2015-03-31
PCT/US2015/034923 WO2015191595A1 (en) 2014-06-09 2015-06-09 A novel formulation of meloxicam

Publications (1)

Publication Number Publication Date
KR20170017915A true KR20170017915A (ko) 2017-02-15

Family

ID=54768708

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167034671A Ceased KR20170017915A (ko) 2014-06-09 2015-06-09 멜록시캄의 신규 제형

Country Status (18)

Country Link
US (8) US9526734B2 (enExample)
EP (1) EP3151835A4 (enExample)
JP (1) JP2017517551A (enExample)
KR (1) KR20170017915A (enExample)
CN (1) CN107073010A (enExample)
AP (1) AP2016009611A0 (enExample)
AU (1) AU2015274838B2 (enExample)
BR (1) BR112016027435A2 (enExample)
CA (1) CA2951383A1 (enExample)
EA (1) EA201692392A1 (enExample)
IL (1) IL248699A0 (enExample)
MA (1) MA39443A1 (enExample)
MX (1) MX2016016212A (enExample)
NZ (1) NZ726610A (enExample)
PH (1) PH12016502336A1 (enExample)
SG (1) SG11201610179QA (enExample)
WO (1) WO2015191595A1 (enExample)
ZA (1) ZA201700022B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN108949699B (zh) 2018-08-03 2020-09-04 江南大学 一种分泌美洛昔康单克隆抗体的杂交瘤细胞株及其应用
CN111346097B (zh) * 2018-12-22 2023-03-24 江苏先声药业有限公司 一种组合物及其制备方法
EP3958841A1 (en) * 2019-04-22 2022-03-02 Mylan Specialty L.P. Meloxicam co-crystal compositions
JP7348703B2 (ja) * 2019-06-28 2023-09-21 エスエス製薬株式会社 メロキシカム含有造粒物
US20210093642A1 (en) * 2019-09-26 2021-04-01 Cadila Healthcare Limited STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
WO2021224815A1 (en) * 2020-05-06 2021-11-11 Cadila Healthcare Limited Stable aqueous parenteral solutions of nonsteroidal anti-inflammatory drug (nsaid)
US20250352478A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
US20250352552A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
CN115844820B (zh) * 2022-11-23 2023-08-29 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172546A (en) 1961-05-19 1965-03-09 Union Carbide Corp Size reduction of biological substances
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IT1082518B (it) 1977-01-25 1985-05-21 Fiat Spa Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
ZA951497B (en) 1994-03-02 1996-08-23 Lilly Co Eli Orally administerable pharmaceutical formulations
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
EP1007049A1 (en) 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
EP1066825A1 (en) 1999-06-17 2001-01-10 The Procter & Gamble Company An anti-microbial body care product
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR100949539B1 (ko) 2000-06-27 2010-03-25 벡투라 리미티드 약학 조성물용 입자의 제조 방법
ATE424811T1 (de) 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2001297844A1 (en) 2000-11-20 2002-12-03 Elan Pharma International Ltd. Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
JP2005504266A (ja) 2001-06-22 2005-02-10 エラン ファーマ インターナショナル，リミティド 小規模ミルまたは微小流体工学を用いる高スループットスクリーニング法
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US6825161B2 (en) 2002-04-26 2004-11-30 Salvona Llc Multi component controlled delivery system for soap bars
WO2004019937A1 (en) 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
WO2004029046A2 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
AU2003297151A1 (en) 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004066981A1 (en) 2003-01-29 2004-08-12 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
DE60309356T2 (de) 2003-06-27 2007-08-30 Bioprogress S.P.A. Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
WO2005004915A2 (en) 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
WO2005016310A1 (en) 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
ATE362395T1 (de) 2003-10-01 2007-06-15 Debio Rech Pharma Sa Vorrichtung und verfahren zur herstellung von partikeln
CA2544627A1 (en) 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP2110124B1 (en) 2004-03-08 2013-07-17 Spiridon Spireas Bioavailable Solid Dosage Forms of Metaxalone
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
WO2006009419A1 (es) 2004-07-19 2006-01-26 Luis Cordova Boone Neumáticos con doble banda de rodamiento
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (en) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Pharmaceutical dosage form comprising meloxicam
WO2007001451A2 (en) 2004-11-09 2007-01-04 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EP1830824B1 (en) 2004-12-31 2016-01-13 Iceutica Pty Ltd. Nanoparticle composition and methods for synthesis thereof
ES2340518T3 (es) 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
BRPI0617208A2 (pt) * 2005-09-30 2011-07-19 Boehringer Ingelheim Vetmed preparação farmacêutica contendo meloxicam
US20080292584A1 (en) 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ATE444736T1 (de) 2005-12-15 2009-10-15 Acusphere Inc Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur parenteralen verabreichung
WO2007070843A2 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007074477A2 (en) 2005-12-29 2007-07-05 Dabur Pharma Limited Metaxalone polymorphs
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
KR20090023729A (ko) 2006-06-23 2009-03-05 엘란 파마 인터내셔널 리미티드 나노입자형 멜록시캄 및 조절 방출형 하이드로코돈을 포함하는 조성물
CN102895194B (zh) 2006-06-30 2015-09-09 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
IN2014MN00380A (enExample) 2006-06-30 2015-06-19 Iceutica Pty Ltd
CN100386312C (zh) 2006-07-18 2008-05-07 上海世景国际贸易有限公司 2，4-二氨基苯磺酸及其盐的合成方法
KR20090027734A (ko) 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
US20110086074A1 (en) 2008-06-02 2011-04-14 Dr. Reddy's Laboratories Ltd. Combinations of niacin and an oxicam
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
IL254371B2 (en) 2009-04-24 2023-09-01 Iceutica Pty Ltd Production of encapsulated nanoparticles on a commercial scale
MY159098A (en) 2009-04-24 2016-12-15 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
AP2015008967A0 (en) * 2009-04-24 2015-12-31 Iceutica Pty Ltd A novel formulation of meloxicam
MX337619B (es) 2009-04-24 2016-03-10 Iceutica Pty Ltd Una formulacion novedosa de diclofenaco.
MA33294B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
NZ595985A (en) 2009-04-24 2014-07-25 Iceutica Pty Ltd A novel formulation of naproxen
CA2759113C (en) 2009-04-24 2017-12-12 Iceutica Pty Ltd A novel formulation of metaxalone
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
KR101873500B1 (ko) 2009-04-24 2018-08-02 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
WO2011026080A1 (en) * 2009-08-31 2011-03-03 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
DK3024440T3 (en) 2013-07-22 2019-03-11 Iceutica Inc METAXALON FORMULATION
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam

Also Published As

Publication number Publication date
EP3151835A1 (en) 2017-04-12
US9649318B2 (en) 2017-05-16
EA201692392A1 (ru) 2017-03-31
EP3151835A4 (en) 2018-01-10
PH12016502336A1 (en) 2017-02-13
US20180050042A1 (en) 2018-02-22
CN107073010A (zh) 2017-08-18
US20170246178A1 (en) 2017-08-31
US9526734B2 (en) 2016-12-27
MX2016016212A (es) 2017-02-23
US20200085835A1 (en) 2020-03-19
MA39443A1 (fr) 2017-10-31
NZ726610A (en) 2020-05-29
ZA201700022B (en) 2018-05-24
SG11201610179QA (en) 2017-01-27
CA2951383A1 (en) 2015-12-17
AU2015274838A1 (en) 2016-12-08
AU2015274838B2 (en) 2019-07-04
JP2017517551A (ja) 2017-06-29
US20230414630A1 (en) 2023-12-28
US20160101110A1 (en) 2016-04-14
US20150352122A1 (en) 2015-12-10
BR112016027435A2 (pt) 2017-10-17
US9808468B2 (en) 2017-11-07
US20250235461A1 (en) 2025-07-24
US20210213028A1 (en) 2021-07-15
WO2015191595A1 (en) 2015-12-17
AP2016009611A0 (en) 2016-12-31
IL248699A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
AU2015274838B2 (en) A novel formulation of meloxicam
DK2421513T3 (en) UNKNOWN FORMULATION WITH INDOMETHACIN
JP6222924B2 (ja) ジクロフェナクの新規製剤
KR20120059452A (ko) 신규 멜록시캄 제제
US20220235017A1 (en) Formulation of metaxalone
HK1242624A1 (en) A novel formulation of meloxicam
OA19000A (en) A novel formulation of meloxicam
HK1233538A1 (zh) 双氯芬酸的新剂型
HK1232808A1 (en) A novel formulation of diclofenac

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161209

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190617

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190617

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I